Olson D, Pöllänen J, Høyer-Hansen G, Rønne E, Sakaguchi K, Wun T C, Appella E, Danø K, Blasi F
Institute of Microbiology, University of Copenhagen, Denmark.
J Biol Chem. 1992 May 5;267(13):9129-33.
The role of the urokinase receptor (uPAR) in the internalization of the urokinase-plasminogen activator inhibitor type-1 (uPA.PAI-1) complex has been investigated. First, exploiting the species specificity of uPA binding, we show that mouse LB6 cells (that express a mouse uPAR) were unable to bind or degrade the human uPA.PAI-1 complex. On the other hand, LB6 clone 19 cells, which express a transfected human uPAR, degraded uPA.PAI-1 complexes with kinetics identical to the human monocytic U937 cells. We also show by immunofluorescence experiments with anti-uPA antibodies that in LB6 clone 19 cells, the uPA.PAI-1 complex is indeed internalized. While at 4 degrees C uPA fluorescence was visible at the cell surface, shift of the temperature to 37 degrees C caused a displacement of the immunoreactivity to the cytoplasmic compartment, with a pattern indicating lysosomal localization. If uPA.PAI-1 internalization/degradation is mediated by uPAR, inhibition of uPA.PAI-1 binding to uPAR should block degradation. Three different treatments, competition with the agonist amino-terminal fragment of uPA, treatment with a monoclonal antibody directed toward the binding domain of uPAR or release of uPAR from the cell surface with phosphatidylinositol-specific phospholipase C completely prevented uPA.PAI-1 degradation. The possibility that a serpin-enzyme complex receptor might be primarily or secondarily involved in the internalization process was excluded since a serpin-enzyme complex peptide failed to inhibit uPA.PAI-1 binding and degradation. Similarly, complexes of PAI-1 with low molecular mass uPA (33 kDa uPA), which lacks the uPAR binding domain, were neither bound nor degraded. Finally we also show that treatment of cells with uPA.PAI-1 complex caused a specific but partial down-regulation of uPAR. A similar result was obtained when PAI-1 was allowed to complex to uPA that had been previously bound to the receptor. The possibility therefore exists that the entire complex uPA.PAI-1-uPAR is internalized. All these data allow us to conclude that internalization of the uPA.PAI-1 complex is mediated by uPAR.
尿激酶受体(uPAR)在尿激酶 - 纤溶酶原激活物抑制剂1型(uPA.PAI - 1)复合物内化过程中的作用已得到研究。首先,利用uPA结合的物种特异性,我们发现小鼠LB6细胞(表达小鼠uPAR)无法结合或降解人uPA.PAI - 1复合物。另一方面,表达转染人uPAR的LB6克隆19细胞以与人单核细胞U937细胞相同的动力学降解uPA.PAI - 1复合物。我们还通过用抗uPA抗体进行免疫荧光实验表明,在LB6克隆19细胞中,uPA.PAI - 1复合物确实被内化。在4℃时,uPA荧光在细胞表面可见,将温度转移至37℃会导致免疫反应性向细胞质区室转移,其模式表明溶酶体定位。如果uPA.PAI - 1的内化/降解是由uPAR介导的,那么抑制uPA.PAI - 1与uPAR的结合应该会阻止降解。三种不同的处理方法,即与uPA的激动剂氨基末端片段竞争、用针对uPAR结合域的单克隆抗体处理或用磷脂酰肌醇特异性磷脂酶C从细胞表面释放uPAR,完全阻止了uPA.PAI - 1的降解。由于丝氨酸蛋白酶抑制剂 - 酶复合物肽未能抑制uPA.PAI - 1的结合和降解,因此排除了丝氨酸蛋白酶抑制剂 - 酶复合物受体可能主要或次要参与内化过程这一可能性。同样,PAI - 1与缺乏uPAR结合域的低分子量uPA(33 kDa uPA)的复合物既不被结合也不被降解。最后,我们还表明用uPA.PAI - 1复合物处理细胞会导致uPAR特异性但部分下调。当PAI - 1与先前已结合到受体的uPA形成复合物时,也获得了类似的结果。因此,存在整个uPA.PAI - 1 - uPAR复合物被内化的可能性。所有这些数据使我们能够得出结论,uPA.PAI - 1复合物的内化是由uPAR介导的。